Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Result of the Reduction in Shareholding of the Shareholders Holding More Than 5% of the Shares" published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 4 December 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purposes only*

Stock Code: 688180 Stock Abbreviation: Junshi Bio Announcement No.: Lin 2025-070

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on the Result of the Reduction in Shareholding of the Shareholders Holding More Than 5% of the Shares

The board of directors, all directors and relevant shareholders of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Important notice:

- Basic shareholding information of the substantial shareholder

Before the plan for the reduction in shareholding, Shanghai Tanying Investment Partnership (LP) ("Shanghai Tanying") held 71,459,326 shares in Shanghai Junshi Biosciences Co., Ltd. (the "Company"), all of which were A shares, accounting for 6.9602% of total share capital of the Company. The aforesaid shares are shares acquired before the initial public offering and listing on the Science and Technology Innovation Board of Shanghai Stock Exchange (the "IPO") of the Company, and the restrictions on sale have been lifted and the shares have been listed for trading since 15 July 2021.

- Result of the plan for the reduction in shareholding

On 15 August 2025, the Company disclosed the "Announcement on the Plan for the Reduction in the Shareholding of the Shareholders Holding more than 5% of the Shares" (Announcement No.: Lin 2025-039) on the website of Shanghai Stock Exchange (www.sse.com.cn). Due to the maturity of the fund and liquidity arrangements, Shanghai Tanying planned to reduce the shareholding in the Company

by no more than 20,533,797 shares in total through block trading, and the total reduction ratio did not exceed 2% of the total share capital of the Company. The duration of reduction in shareholding was from 5 September 2025 to 4 December 2025.

As of the date of this announcement, the time period of the plan for the reduction in shareholding has expired. The Company received the "Notice on the Result of the Reduction in Shareholding"（《關於減持股份結果的告知函》）issued by Shanghai Tanying recently. During the duration of the plan for the reduction in shareholding, Shanghai Tanying reduced 12,000,000 A shares of the Company in total through block trading, and the total reduction ratio accounted for 1.1688% of the total share capital of the Company.

I. Basic Information on the Subject of the Reduction in Shareholding Before the Reduction in Shareholding

Name of shareholder	Shanghai Tanying
Capacity of shareholder	Controlling shareholder, actual controller and party acting in concert □Yes √No Shareholder directly holding more than 5% of shares √Yes □No Director, supervisor and senior management □Yes √No Others: Not applicable
Number of shares held	71,459,326 shares
Shareholding percentage	6.9602%
Source of shares currently held	Acquired prior to the IPO: 71,459,326 shares

The aforesaid subject entity of the reduction in shareholding has parties acting in concert:

	Name of shareholder	Number of shares held (shares)	Shareholding percentage	Reasons for acting in concert
Group 1	Shanghai Tanying	71,459,326	6.9602%	The executive partner of Shanghai Tanying is Shanghai Loyal Valley Investment Management Co., Ltd., and the actual controller is Mr. Lin Lijun. Shares of the Company held by Shanghai Tanying are A shares. Loyal Valley Capital Advantage Fund II LP and LVC Renaissance Fund LP are partnerships beneficially controlled by Mr. Lin Lijun, and the nature of the shares held by them is H shares.
	Loyal Valley Capital Advantage Fund II LP	7,842,673	0.7639%	
	LVC Renaissance Fund LP	7,916,000	0.7710%	
	Total	87,217,999	8.4951%	—

II. Result of the Plan for the Reduction in Shareholding

(i) Major shareholders disclose the result of the plan for the reduction due to the following matter:

Disclosed share reduction period has expired

Name of shareholder	Shanghai Tanying
First disclosure date of the plan for the reduction in shareholding	15 August 2025
Number of shares reduced	12,000,000 shares

(share)	
Duration of reduction in shareholding	5 September 2025～22 September 2025
Methods for reduction in shareholding and corresponding number of shares reduced	For reduction in shareholding through block trades: 12,000,000 shares
Price range of reduction in shareholding (RMB/share)	RMB 43.13～48.46 per share
Total amount of reduction in shareholding	RMB 557,940,000.00
Completion of reduction in shareholding	Not yet completed: 8,533,797 shares
Percentage of reduction in shareholding	1.1688%
Percentage of proposed reduction in shareholding	Not more than: 2%
Current shareholding	59,459,326 shares
Current shareholding percentage	5.7914%

(ii) Whether the reduction in shareholding is in compliance with the relevant laws and regulations and the business rules of the stock exchange √Yes □No

(iii) Whether the actual reduction in shareholding is consistent with the plan and undertakings previously disclosed √Yes □No

(iv) Whether the reduction was not implemented after the expiration of the reduction period □Not implemented √Implemented

(v) Whether the actual reduction failed to achieve the minimum reduction quantity (ratio) specified in the reduction plan □Not achieved √Achieved

(vi) Whether to terminate the share reduction plan in advance □Yes √No

(vii) Whether there is any violation of the plan or other undertakings □Yes √No

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

5 December 2025